JP2019536770A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536770A5 JP2019536770A5 JP2019524074A JP2019524074A JP2019536770A5 JP 2019536770 A5 JP2019536770 A5 JP 2019536770A5 JP 2019524074 A JP2019524074 A JP 2019524074A JP 2019524074 A JP2019524074 A JP 2019524074A JP 2019536770 A5 JP2019536770 A5 JP 2019536770A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- item
- heteroalkyl
- amino
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003839 salts Chemical class 0.000 claims description 53
- 125000000217 alkyl group Chemical group 0.000 claims description 40
- 229910052739 hydrogen Inorganic materials 0.000 claims description 28
- 239000001257 hydrogen Substances 0.000 claims description 28
- -1 selenoalkyl Chemical group 0.000 claims description 24
- 125000003342 alkenyl group Chemical group 0.000 claims description 19
- 125000003118 aryl group Chemical group 0.000 claims description 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 19
- 150000002431 hydrogen Chemical class 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 125000002252 acyl group Chemical group 0.000 claims description 14
- 125000000304 alkynyl group Chemical group 0.000 claims description 13
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 13
- 125000003277 amino group Chemical group 0.000 claims description 12
- 125000001475 halogen functional group Chemical group 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 10
- 125000000524 functional group Chemical group 0.000 claims description 10
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 9
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 150000003573 thiols Chemical class 0.000 claims description 8
- 108091023037 Aptamer Proteins 0.000 claims description 6
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 150000004665 fatty acids Chemical class 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 239000007790 solid phase Substances 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- 229940124530 sulfonamide Drugs 0.000 claims description 6
- 150000003456 sulfonamides Chemical class 0.000 claims description 6
- 125000004423 acyloxy group Chemical group 0.000 claims description 5
- 125000003282 alkyl amino group Chemical group 0.000 claims description 5
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 5
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 5
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 5
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 125000006684 polyhaloalkyl group Polymers 0.000 claims description 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 5
- 108010043958 Peptoids Proteins 0.000 claims description 4
- 239000011324 bead Substances 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 239000002777 nucleoside Substances 0.000 claims description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 3
- 125000004001 thioalkyl group Chemical group 0.000 claims description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000005041 acyloxyalkyl group Chemical group 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- 125000005353 silylalkyl group Chemical group 0.000 claims description 2
- 238000000034 method Methods 0.000 description 34
- 150000001875 compounds Chemical class 0.000 description 13
- 238000003776 cleavage reaction Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical group CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000012808 vapor phase Substances 0.000 description 2
- VODKOOOHHCAWFR-UHFFFAOYSA-N 2-iodoacetonitrile Chemical compound ICC#N VODKOOOHHCAWFR-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical group C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000008049 diazo compounds Chemical group 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 125000005545 phthalimidyl group Chemical group 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662419861P | 2016-11-09 | 2016-11-09 | |
| US62/419,861 | 2016-11-09 | ||
| PCT/US2017/060721 WO2018089554A1 (en) | 2016-11-09 | 2017-11-08 | Pre-assembled, protected, chemically stable, chemoselective linkers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019536770A JP2019536770A (ja) | 2019-12-19 |
| JP2019536770A5 true JP2019536770A5 (enExample) | 2020-12-17 |
Family
ID=62109408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019524074A Withdrawn JP2019536770A (ja) | 2016-11-09 | 2017-11-08 | 予め会合され、保護され、化学的に安定した、官能基選択的リンカー |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12037311B2 (enExample) |
| EP (1) | EP3538536A4 (enExample) |
| JP (1) | JP2019536770A (enExample) |
| KR (1) | KR20190082871A (enExample) |
| CN (2) | CN110072870A (enExample) |
| AU (1) | AU2017359448A1 (enExample) |
| CA (1) | CA3043373A1 (enExample) |
| WO (1) | WO2018089554A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019528428A (ja) | 2016-06-20 | 2019-10-10 | ヘルステル・インコーポレイテッドＨｅａｌｔｈｔｅｌｌ Ｉｎｃ． | 自己免疫疾患の鑑別診断方法 |
| US11774446B2 (en) | 2016-06-20 | 2023-10-03 | Cowper Sciences Inc. | Methods for diagnosis and treatment of autoimmune diseases |
| US12037311B2 (en) | 2016-11-09 | 2024-07-16 | Cowper Sciences Inc. | Pre-assembled, protected, chemically stable, chemoselective linkers |
| US11359112B2 (en) | 2016-11-09 | 2022-06-14 | Cowper Sciences Inc. | Coatings with tunable amine density |
| WO2018089858A1 (en) | 2016-11-11 | 2018-05-17 | Healthtell Inc. | Methods for identifying candidate biomarkers |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
| US5981478A (en) | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
| US5571639A (en) | 1994-05-24 | 1996-11-05 | Affymax Technologies N.V. | Computer-aided engineering system for design of sequence arrays and lithographic masks |
| US5932546A (en) | 1996-10-04 | 1999-08-03 | Glaxo Wellcome Inc. | Peptides and compounds that bind to the thrombopoietin receptor |
| US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
| US6824866B1 (en) | 1999-04-08 | 2004-11-30 | Affymetrix, Inc. | Porous silica substrates for polymer synthesis and assays |
| GB0001513D0 (en) | 2000-01-25 | 2000-03-15 | Univ Cranfield | Rational design of mips using computational approach |
| CA2410887C (en) | 2000-06-02 | 2012-07-24 | Bracco Research Usa | Compounds for targeting endothelial cells, compositions containing the same and methods for their use |
| US20030219816A1 (en) | 2001-07-02 | 2003-11-27 | Keith Solomon | Composite microarray slides |
| CN1125488C (zh) | 2000-08-25 | 2003-10-22 | 中国科学院化学研究所 | 一种半导体封装用的液体环氧组合物及其用途 |
| JP4398644B2 (ja) | 2001-04-06 | 2010-01-13 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア | ＥｒｂＢ界面ペプチド擬態およびその使用方法 |
| US20030003223A1 (en) | 2001-04-07 | 2003-01-02 | The Regents Of The University Of California | Methods and compositions for binding histidine-containing proteins to substrates |
| GB0121602D0 (en) | 2001-09-06 | 2001-10-24 | Randox Lab Ltd | Molecular array |
| AU2003233498A1 (en) | 2002-06-10 | 2003-12-22 | Phynexus, Inc. | Biomolecule open channel solid phase extraction systems and methods |
| US20060013971A1 (en) | 2002-10-25 | 2006-01-19 | Tienteh Chen | Porous inkjet recording material |
| AU2003300815A1 (en) | 2002-12-05 | 2004-06-30 | Incyte Corporation | Protein modification and maintenance molecules |
| KR100529600B1 (ko) | 2003-01-23 | 2005-11-22 | 정만길 | 디옥소아테미시닌 유사체, 그의 제조방법 및 그를포함하는 항암제 |
| JP4006523B2 (ja) | 2003-04-10 | 2007-11-14 | 独立行政法人産業技術総合研究所 | タンパク質アレイ及びその作製方法 |
| WO2005050224A2 (en) | 2003-11-13 | 2005-06-02 | Epitome Biosystems Inc. | Small molecule and peptide arrays and uses thereof |
| JP5553954B2 (ja) | 2003-11-15 | 2014-07-23 | ポリファー リミテッド | テンプレート固定β−ヘアピンループ模倣体とそのファージディスプレイにおける使用 |
| CN103626884B (zh) | 2005-02-23 | 2016-05-18 | 利普生技术有限公司 | 用于蛋白质衍生和缀合的活化的唾液酸衍生物 |
| MX2007011307A (es) * | 2005-03-18 | 2007-10-08 | Novo Nordisk As | Compuestos de glp-1 extendidos. |
| US7507480B2 (en) | 2005-05-31 | 2009-03-24 | Brookhaven Science Associates, Llc | Corrosion-resistant metal surfaces |
| KR100671659B1 (ko) | 2005-12-21 | 2007-01-19 | 삼성에스디아이 주식회사 | 데이터 구동부 및 이를 이용한 유기 발광 표시장치와 그의구동방법 |
| US7923054B2 (en) | 2006-04-19 | 2011-04-12 | Gore Enterprise Holdings, Inc. | Functional porous substrates for attaching biomolecules |
| WO2007144685A1 (en) | 2006-06-13 | 2007-12-21 | Commissariat A L'energie Atomique | Cd4 mimic peptides and their uses |
| WO2007149982A2 (en) | 2006-06-22 | 2007-12-27 | The Brigham And Women's Hospital, Inc. | Diagnosis of autoimmune disease |
| JP2008028123A (ja) | 2006-07-20 | 2008-02-07 | Sanyo Electric Co Ltd | 半導体集積回路装置の製造方法 |
| EP2089712A4 (en) | 2006-11-22 | 2010-09-22 | Life Technologies Corp | BIOMARKERS OF AUTOIMMUNE DISEASES |
| US20100093554A1 (en) | 2007-06-01 | 2010-04-15 | Keting Chu | Methods for identifying biomarkers, autoantibody signatures, and stratifying subject groups using peptide arrays |
| EP2158326B1 (en) | 2007-06-21 | 2012-06-20 | The Board of Trustees of The Leland Stanford Junior University | Biomarkers for rheumatoid arthritis |
| JP2011001344A (ja) | 2009-04-30 | 2011-01-06 | L'oreal Sa | アミノトリアルコキシシランまたはアミノトリアルケニルオキシシラン組成物を用いたヒトケラチン繊維の明色化および／または着色ならびに装置 |
| US20120190574A1 (en) | 2009-06-19 | 2012-07-26 | The Arizona Board of Regents, A body Corporate of the State of Arizona for and on behalf of Arizona | Compound Arrays for Sample Profiling |
| CA2768149A1 (en) | 2009-07-14 | 2011-01-20 | Lucia Irene Gonzalez | Stereoisomer peptides and their polymer conjugates for hiv disease |
| WO2011041586A1 (en) | 2009-09-30 | 2011-04-07 | Virogenomics, Inc. | Electromagnetic detection of analytes |
| US8698320B2 (en) | 2009-12-07 | 2014-04-15 | Henkel IP & Holding GmbH | Curable resin compositions useful as underfill sealants for use with low-k dielectric-containing semiconductor devices |
| EP2539470B1 (en) | 2010-02-24 | 2017-02-22 | The Board of Trustees of The Leland Stanford Junior University | Methods for autoimmune disease diagnosis, prognosis, and treatment |
| US20120237555A1 (en) | 2011-03-16 | 2012-09-20 | David Williams | Surface coating for biomolecule immobilisation and minimisation of non-specific binding on surfaces for biomedical diagnostics |
| US9346892B2 (en) | 2011-03-18 | 2016-05-24 | Roche Nimble Gen, Inc. | Methods for synthesis of an oligopeptide microarray |
| US9482666B2 (en) | 2011-11-22 | 2016-11-01 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | High throughput selection of specific cell binding and lytic polypeptides |
| CA3191015A1 (en) | 2012-02-07 | 2013-08-15 | Vibrant Holdings, Llc | Substrates, peptide arrays, and methods |
| US20130310265A1 (en) | 2012-03-21 | 2013-11-21 | North Carolina State University | Methods of preparing cyclic peptides and uses thereof |
| CN107973856B (zh) | 2012-07-04 | 2021-11-23 | 弗·哈夫曼-拉罗切有限公司 | 共价连接的抗原-抗体缀合物 |
| US20140087963A1 (en) | 2012-08-29 | 2014-03-27 | Arizona Board of Regents, a body Corporate of the State of Arizona, Acting for and on Behalf of Ariz | Immunosignaturing: a path to early diagnosis and health monitoring |
| EP3604634A1 (en) * | 2012-09-05 | 2020-02-05 | Arizona Board of Regents, a Body Corporate of the State of Arizona, acting for and on behalf of Arizona State University | Methods for discovering therapeutic targets |
| WO2014062981A1 (en) | 2012-10-17 | 2014-04-24 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | In situ chemical patterning |
| WO2014144383A1 (en) | 2013-03-15 | 2014-09-18 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Non-covalent patterned chemical features and use thereof in maldi-based quality control |
| JP6656733B2 (ja) | 2013-08-05 | 2020-03-04 | ツイスト バイオサイエンス コーポレーション | 新規合成した遺伝子ライブラリ |
| WO2016011364A1 (en) | 2014-07-18 | 2016-01-21 | Cdi Laboratories, Inc. | Methods and compositions to identify, quantify, and characterize target analytes and binding moieties |
| DK3177640T3 (da) | 2014-08-08 | 2020-08-10 | Univ Leland Stanford Junior | Pd-1-midler med høj affinitet og anvendelsesfremgangsmåder |
| US20160367961A1 (en) | 2015-04-23 | 2016-12-22 | Roche Sequencing Solutions, Inc. | Method and composition for peptide cyclization and protease treatment |
| US10094825B2 (en) | 2015-07-30 | 2018-10-09 | The Florida International University Board Of Trustees | Predictive biomarkers for detection of organ damage in autoimmune illnesses and other diseases |
| AU2017240164A1 (en) | 2016-04-01 | 2018-11-15 | HealthTell, Inc. | Array-based peptide libraries for therapeutic antibody characterization |
| US12037311B2 (en) | 2016-11-09 | 2024-07-16 | Cowper Sciences Inc. | Pre-assembled, protected, chemically stable, chemoselective linkers |
| US11359112B2 (en) | 2016-11-09 | 2022-06-14 | Cowper Sciences Inc. | Coatings with tunable amine density |
| CN111051341A (zh) | 2017-06-19 | 2020-04-21 | 健康之语公司 | 用于鉴别诊断的免疫特征 |
| EP3749676A4 (en) | 2018-02-09 | 2021-12-22 | Healthtell Inc. | NETWORK BASED CYCLIC PEPTIDE BANKS |
| CN113677691A (zh) | 2018-11-14 | 2021-11-19 | 库博科学公司 | 选择功能界面模拟物的方法及其组合物 |
-
2017
- 2017-11-08 US US16/348,484 patent/US12037311B2/en active Active
- 2017-11-08 EP EP17870322.9A patent/EP3538536A4/en not_active Withdrawn
- 2017-11-08 CA CA3043373A patent/CA3043373A1/en not_active Abandoned
- 2017-11-08 AU AU2017359448A patent/AU2017359448A1/en not_active Abandoned
- 2017-11-08 WO PCT/US2017/060721 patent/WO2018089554A1/en not_active Ceased
- 2017-11-08 KR KR1020197016417A patent/KR20190082871A/ko not_active Withdrawn
- 2017-11-08 CN CN201780077556.2A patent/CN110072870A/zh active Pending
- 2017-11-08 CN CN202310471997.8A patent/CN116514861A/zh active Pending
- 2017-11-08 JP JP2019524074A patent/JP2019536770A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019536770A5 (enExample) | ||
| JP2004501869A (ja) | ヒドラジンベース及びカルボニルベースの二官能性架橋剤 | |
| JP2004535193A (ja) | 鋳型化された分子およびかかる分子の使用方法 | |
| JP2004517089A5 (enExample) | ||
| JPH09511228A (ja) | 窒素を含有する結合を有するオリゴマー化合物 | |
| US11560560B2 (en) | Target binding moiety compositions and methods of use | |
| JP2003525945A5 (enExample) | ||
| JP2020525502A5 (enExample) | ||
| CN100509761C (zh) | 标记试剂,合成该试剂的方法以及检测生物分子的方法 | |
| JP2019536860A5 (enExample) | ||
| WO2018051569A1 (ja) | 分泌型免疫グロブリンＡ（ｓＩｇＡ）結合核酸分子、ｓＩｇＡ分析用センサ、およびｓＩｇＡの分析方法 | |
| AU2004272465B2 (en) | Size-controlled macromolecule | |
| AU9264698A (en) | Aminoalkyltrialkylsilylcellulose and a process for coating surfaces | |
| US20120035362A1 (en) | Phosphoramidite derivatives of folic acid | |
| JP2009516008A5 (enExample) | ||
| JP2009510219A5 (enExample) | ||
| JP5196287B2 (ja) | 光分解性カップリング剤 | |
| JPH09510693A (ja) | アミンイミド含有分子のモジュール設計および合成 | |
| US9574236B2 (en) | Isolation of RNA-protein complexes using cross-linking reagents and oligonucleotides | |
| WO2005092910A1 (fr) | Réactifs de marquage, procédés de synthèse de tels réactifs et procédés de détection de molécules biologiques | |
| US20190233818A1 (en) | Improved pna probe | |
| US8853132B2 (en) | Directed synthesis of oligophosphoramidate stereoisomers | |
| CA2371222C (fr) | Support solide fonctionnalise pour la synthese d'alpha-oxoaldehydes | |
| US7892737B2 (en) | Compositions, kits and methods pertaining to stability modulation of PNA oligomer/nucleic acid complexes | |
| JP5251125B2 (ja) | ユニバーサル塩基含有ポリマー |